A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation
Matthew S. Davids(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), John Koreth(Otsuka (Japan)), Yi‐Bin Chen(Massachusetts General Hospital), Vincent T. Ho(Dana-Farber Cancer Institute), Asad Bashey, Haesook T. Kim(Dana-Farber Cancer Institute), David Avigan(Beth Israel Deaconess Medical Center), Philippe Armand(Harvard University), Joseph H. Antin(Dana-Farber Cancer Institute), Alexander Lukez(Dana-Farber Cancer Institute), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Nicole R. LeBoeuf(Dana-Farber Brigham Cancer Center), Caitlin Costello(University of California San Diego), Rebecca Liguori(Dana-Farber Cancer Institute), Peter A. McSweeney(Colorado Blood Cancer Institute), Jerome Ritz(Dana-Farber Cancer Institute), Edward D. Ball(Sheba Medical Center), Corey Cutler(Harvard University)
Cited by 11
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k